Porciani and colleagues show that anti-EGFR aptamers are a feasible way to target EGFR-mutant NSCLC. These aptamers show promise as reagents for diagnostic and therapeutic development to address factors that contribute to poor survival rates in a subset of NSCLC patients, such as therapeutic resistance.
All Keywords
【저자키워드】 Aptamers, Non-small cell lung cancer, Targeted delivery, biodistribution, Molecular engineering, oligonucleotides, MT: Delivery Strategies, EGFR resistance mutations, tumor cell-surface receptors,
【저자키워드】 Aptamers, Non-small cell lung cancer, Targeted delivery, biodistribution, Molecular engineering, oligonucleotides, MT: Delivery Strategies, EGFR resistance mutations, tumor cell-surface receptors,